|
|
基于双硫死亡相关lncRNA的骨肉瘤预后模型构建及验证
|
Abstract:
目的：探索双硫死亡相关lncRNAs (DRLs)在骨肉瘤(Osteosarcoma, OS)患者中的预后价值。方法：从TCGA数据库中提取OS患者的基因表达和相关临床数据，筛选预后相关DRLs基因，构建预后模型并进行验证。qRT-PCR分析检测相关DRLs在细胞及组织中的表达。CCK-8实验检测si-ASB16.AS1对MG-63细胞增殖能力的影响。采用Kaplan-Meier法绘制生存曲线，Cox回归用于分析影响骨肉瘤患者预后的因素。结果：筛选出6个预后相关DRLs (RP11.304F15.6、RP11.750H9.5、RP11.313F23.4、RP11.46C2.47、ASB16.AS1和RP11.452C13.1)用于构建预后模型。ROC分析表明，该模型具有较强的预测能力。qRT-PCR分析表明6个DRLs在OS细胞系中表达上调，si-ASB16.AS1可抑制MG-63细胞增殖。并且，ASB16.AS1在OS患者癌组织中的表达也是上调的，ASB16.AS1高表达的OS患者总体生存时间显著短于低表达患者，ASB16.AS1是OS患者一个独立的预后生物标志物。结论：本研究确定了6个DRLs作为OS预后的标志，构建了一个有价值的OS预后模型；并发现ASB16.AS1可参与OS细胞的增殖，是OS患者一个独立的预后生物标志物。
Objective: To explore the prognostic value of disulfide death related lncRNAs (DRLs) in patients with osteosarcoma (OS). Methods: The gene expression and related clinical data of OS patients were extracted from TCGA database, and prognostic related DRLs genes were screened to construct a prognostic model. The expression of related DRLs in cells and tissues was detected by qRT-PCR. The effect of si-ASB16.AS1 on the proliferation of MG-63 cells was detected by CCK-8 assay. Kaplan-Meier method was used to draw the survival curve, and Cox regression was used to analyze the factors affecting the prognosis of patients with OS. Results: Six prognostic related DRLs (RP11.304F15.6, RP11.750H9.5, RP11.313F23.4, RP11.46C2.47, ASB16.AS1, and RP11.452C13.1) were selected for constructing a prognostic model. ROC analysis showed that the model had a strong predictive ability. qRT-PCR analysis showed that the expression of six DRLs was up-regulated in OS cell lines, and si-ASB16.AS1 inhibited the proliferation of MG-63 cells. The overall survival time of OS patients with high ASB16.AS1 expression is significantly shorter than that of patients with low ASB16.AS1 expression. Conclusion: 6 DRLs were identified as prognostic markers of OS, and a valuable prognostic model of OS was constructed. It was found that ASB16.AS1 can participate in the proliferation of OS cells and is an independent prognostic biomarker in patients with OS.
| [1] | Lin, H., Wu, T., Peng, L., Su, W., Wang, Y., Li, X., et al. (2020) Lnc-MAP6-1:3 Knockdown Inhibits Osteosarcoma Progression by Modulating Bax/Bcl-2 and Wnt/β-Catenin Pathways. International Journal of Medical Sciences, 17, 2248-2256. https://doi.org/10.7150/ijms.47405 |
| [2] | Shoaib, Z., Fan, T.M. and Irudayaraj, J.M.K. (2021) Osteosarcoma Mechanobiology and Therapeutic Targets. British Journal of Pharmacology, 179, 201-217. https://doi.org/10.1111/bph.15713 |
| [3] | Lin, H., Wei, X., Ye, J., Chen, J., Huang, J., Wu, T., et al. (2024) Lnc-CLSTN2-1: 1 Promotes Osteosarcoma Progression by Disrupting Redox Balance through PI3K/AKT Signaling Pathway. Journal of Cancer, 15, 1287-1298. https://doi.org/10.7150/jca.91579 |
| [4] | Zhou, H., Sun, L. and Wan, F. (2019) Molecular Mechanisms of TUG1 in the Proliferation, Apoptosis, Migration and Invasion of Cancer Cells (Review). Oncology Letters, 18, 4393-4402. https://doi.org/10.3892/ol.2019.10848 |
| [5] | Shirvaliloo, M. (2023) Lncrna H19 Promotes Tumor Angiogenesis in Smokers by Targeting Anti-Angiogenic Mirnas. Epigenomics, 15, 61-73. https://doi.org/10.2217/epi-2022-0145 |
| [6] | Wan, N., Liu, Q., Shi, J. and Wang, S. (2024) LncRNA SNHG25 Predicts Poor Prognosis and Promotes Progression in Osteosarcoma via the miR-497-5p/SOX4 Axis. Combinatorial Chemistry & High Throughput Screening, 27, 725-744. https://doi.org/10.2174/1386207326666230602122618 |
| [7] | Zhao, A., Liu, W., Cui, X., Wang, N., Wang, Y., Sun, L., et al. (2020) LncRNA TUSC7 Inhibits Osteosarcoma Progression through the miR-181a/RASSF6 Axis. International Journal of Molecular Medicine, 47, 583-594. https://doi.org/10.3892/ijmm.2020.4825 |
| [8] | Meng, Y., Chen, X. and Deng, G. (2023) Disulfidptosis: A New Form of Regulated Cell Death for Cancer Treatment. Molecular Biomedicine, 4, Article No. 18. https://doi.org/10.1186/s43556-023-00132-4 |
| [9] | Feng, Z., Zhao, Q., Ding, Y., Xu, Y., Sun, X., Chen, Q., et al. (2023) Identification a Unique Disulfidptosis Classification Regarding Prognosis and Immune Landscapes in Thyroid Carcinoma and Providing Therapeutic Strategies. Journal of Cancer Research and Clinical Oncology, 149, 11157-11170. https://doi.org/10.1007/s00432-023-05006-4 |
| [10] | Wang, T., Guo, K., Zhang, D., Wang, H., Yin, J., Cui, H., et al. (2023) Disulfidptosis Classification of Hepatocellular Carcinoma Reveals Correlation with Clinical Prognosis and Immune Profile. International Immunopharmacology, 120, Article ID: 110368. https://doi.org/10.1016/j.intimp.2023.110368 |
| [11] | Liu, F., Yuan, D., Liu, X., Zhuo, S., Liu, X., Sheng, H., et al. (2023) A Demonstration Based on Multi-Omics Transcriptome Sequencing Data Revealed Disulfidptosis Heterogeneity within the Tumor Microenvironment of Esophageal Squamous Cell Carcinoma. Discover Oncology, 14, Article No. 96. https://doi.org/10.1007/s12672-023-00711-5 |
| [12] | Goldman, M.J., Craft, B., Hastie, M., Repečka, K., McDade, F., Kamath, A., et al. (2020) Visualizing and Interpreting Cancer Genomics Data via the Xena Platform. Nature Biotechnology, 38, 675-678. https://doi.org/10.1038/s41587-020-0546-8 |
| [13] | Chen, J., Zhang, J., Gao, Y., Li, Y., Feng, C., Song, C., et al. (2020) LncSEA: A Platform for Long Non-Coding RNA Related Sets and Enrichment Analysis. Nucleic Acids Research, 49, D969-D980. https://doi.org/10.1093/nar/gkaa806 |
| [14] | Tibshirani, R. (1997) The Lasso Method for Variable Selection in the Cox Model. Statistics in Medicine, 16, 385-395. https://doi.org/10.1002/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3 |
| [15] | Therneau, T.M. and Lumley, T. (2015) Package “Survival”. https://github.com/therneau/survival |
| [16] | Li, S., Zhang, H., Liu, J. and Shang, G. (2023) Targeted Therapy for Osteosarcoma: A Review. Journal of Cancer Research and Clinical Oncology, 149, 6785-6797. https://doi.org/10.1007/s00432-023-04614-4 |
| [17] | Liu, S., Wang, S., Guo, J., Wang, C., Zhang, H., Lin, D., et al. (2024) Crosstalk among Disulfidptosis-Related LncRNAs in Lung Adenocarcinoma Reveals a Correlation with Immune Profile and Clinical Prognosis. Non-Coding RNA Research, 9, 772-781. https://doi.org/10.1016/j.ncrna.2024.03.006 |
| [18] | Wang, Y., Deng, Y., Xie, H. and Cao, S. (2023) Hub Gene of Disulfidptosis-Related Immune Checkpoints in Breast Cancer. Medical Oncology, 40, Article No. 222. https://doi.org/10.1007/s12032-023-02073-y |
| [19] | Xue, W., Qiu, K., Dong, B., Guo, D., Fu, J., Zhu, C., et al. (2023) Disulfidptosis-Associated Long Non-Coding RNA Signature Predicts the Prognosis, Tumor Microenvironment, and Immunotherapy and Chemotherapy Options in Colon Adenocarcinoma. Cancer Cell International, 23, Article No. 218. https://doi.org/10.1186/s12935-023-03065-8 |
| [20] | Liu, L., Liu, J., Lyu, Q., Huang, J., Chen, Y., Feng, C., et al. (2023) Disulfidptosis-Associated LncRNAs Index Predicts Prognosis and Chemotherapy Drugs Sensitivity in Cervical Cancer. Scientific Reports, 13, Article No. 12470. https://doi.org/10.1038/s41598-023-39669-3 |
| [21] | Xiao, L., Yin, W., Chen, X., Zhang, X., Zhang, C., Yu, Z., et al. (2023) A Disulfidptosis-Related LncRNA Index Predicting Prognosis and the Tumor Microenvironment in Colorectal Cancer. Scientific Reports, 13, Article No. 20135. https://doi.org/10.1038/s41598-023-47472-3 |
| [22] | Zhang, H., Pan, J. and Zhu, T. (2023) A disulfidptosis-Related LncRNA Prognostic Model to Predict Survival and Response to Immunotherapy in Lung Adenocarcinoma. Frontiers in Pharmacology, 14, Article 1254119. https://doi.org/10.3389/fphar.2023.1254119 |
| [23] | Deng, Y., Yuan, W., Ren, E., Wu, Z., Zhang, G. and Xie, Q. (2021) A Four-Methylated LncRNA Signature Predicts Survival of Osteosarcoma Patients Based on Machine Learning. Genomics, 113, 785-794. https://doi.org/10.1016/j.ygeno.2020.10.010 |
| [24] | Yu, M., Shi, C., Xu, D., Lin, X., Ji, T., Shi, Z., et al. (2021) LncRNA ASB16-AS1 Drives Proliferation, Migration, and Invasion of Colorectal Cancer Cells through Regulating miR-185-5p/TEAD1 Axis. Cell Cycle, 21, 1-11. https://doi.org/10.1080/15384101.2021.1973700 |
| [25] | Fan, Y., Wang, L., Han, X., Ma, H., Zhang, N. and She, L. (2023) LncRNA ASB16-AS1 Accelerates Cellular Process and Chemoresistance of Ovarian Cancer Cells by Regulating GOLM1 Expression via Targeting miR-3918. Biochemical and Biophysical Research Communications, 675, 1-9. https://doi.org/10.1016/j.bbrc.2023.06.068 |
| [26] | Jia, Z., Wang, P.S., Yang, Y., et al. (2021) LncRNA ASB16-AS1 Regulates the Proliferation, Migration and Invasion of Esophageal Cancer Cells by Targeting miR-1258. Chinese Journal of Oncology, 43, 762-768. |
| [27] | Wu, L., Liao, W., Wang, X., Zhao, Y., Pang, J., Chen, Y., et al. (2021) Expression, Prognosis Value, and Immune Infiltration of LncRNA ASB16-AS1 Identified by Pan-Cancer Analysis. Bioengineered, 12, 10302-10318. https://doi.org/10.1080/21655979.2021.1996054 |
| [28] | Zhang, J. and Lou, W. (2020) A Key mRNA-miRNA-LncRNA Competing Endogenous RNA Triple Sub-Network Linked to Diagnosis and Prognosis of Hepatocellular Carcinoma. Frontiers in Oncology, 10, Article 340. https://doi.org/10.3389/fonc.2020.00340 |
| [29] | Zhang, D., Zhou, H., Liu, J. and Mao, J. (2019) Long Noncoding RNA ASB16-AS1 Promotes Proliferation, Migration, and Invasion in Glioma Cells. BioMed Research International, 2019, Article ID: 5437531. https://doi.org/10.1155/2019/5437531 |
| [30] | Elabd, N.S., Soliman, S.E., Elhamouly, M.S., Gohar, S.F., Elgamal, A., Alabassy, M.M., et al. (2022) Long Non-Coding RNAs ASB16-AS1 and AFAP1-AS1: Diagnostic, Prognostic Impact and Survival Analysis in Colorectal Cancer. The Application of Clinical Genetics, 15, 97-109. https://doi.org/10.2147/tacg.s370242 |
